A Single-Arm, Open-Label, Phase 1 Study Of The Safety, Efficacy, And Cellular Kinetics/Pharmacodynamics Of ALLO-715 To Evaluate An Anti-BCMA Allogeneic CAR T Cell Therapy In Subjects With Relapsed/Refractory Multiple Myeloma Read more
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of BB2121 In Subjects With Multiple Myeloma (Karmma-2) Read more
A Phase 3, Multicenter, Randomized, Open Label Study To Compare The Efficacy And Safety Of Bb2121 Versus Standard Triplet Regimens In Subjects With Relapsed And Refractory Multiple Myeloma Read more
A Phase 1b-2 Study Of The ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), And The Bruton Tyrosine Kinase Inhibitor, Ibrutinib, In Patients With B-Cell Lymphoid Malignancies Read more
A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma Read more
An Open-Label, Dose Escalation And Dose Expansion Trial Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Orally Administered CA-4948 In Patients With Relapsed Or Refractory Hematologic Malignancies Read more
A Phase 1b/2, Open-Label Trial To Assess The Safety And Preliminary Efficacy Of Epcoritamab (GEN3013; Duobody®-CD3xCD20) In Combination With Other Agents In Subjects With B-Cell Non-Hodgkin Lymphoma Read more
